摘要
目的探究不同他汀类药物对血糖影响及机制的研究。方法 120例非糖尿病冠心病患者,根据治疗方法不同分为甲组、乙组、丙组,各40例。甲组采用匹伐他汀进行治疗,乙组采用瑞舒伐他汀进行治疗,丙组采用阿托伐他汀进行治疗。3个月后,对比三组患者的低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖、餐后2 h血糖、糖化血红蛋白、胰岛素值。结果治疗前,三组患者的LDL-C、TC、HDL-C、TG比较差异无统计学意义(P>0.05)。治疗后,乙组与丙组患者的LDL-C、TC、HDL-C、TG对比差异无统计学意义(P>0.05);但甲组患者的LDL-C、TC、HDL-C、TG与乙组、丙组对比,差异具有统计学意义(P<0.05)。治疗前,三组患者的糖化血红蛋白、空腹血糖、胰岛素值、餐后2 h血糖比较差异无统计学意义(P>0.05)。治疗后,乙组与丙组患者的糖化血红蛋白、空腹血糖、胰岛素值、餐后2 h血糖对比差异无统计学意义(P>0.05);但甲组患者的糖化血红蛋白(3.89±0.70)%、空腹血糖(4.62±1.21)mmol/L、胰岛素值(27.54±24.10)m U/L、餐后2 h血糖(5.98±1.23)mmol/L,均显著低于乙组的(4.90±0.44)%、(5.22±1.89)mmol/L、(30.90±26.60)m U/L、(6.39±1.01)mmol/L和丙组的(4.32±0.51)%、(5.15±1.71)mmol/L、(30.10±25.12)m U/L、(6.22±1.22)mmol/L,差异具有统计学意义(P<0.05)。结论针对非糖尿病冠心病患者,采用匹伐他汀治疗,可加快患者康复速度,缓解临床症状,改善患者生活质量,不增加冠心病患者新发糖尿病风险,对患者糖代谢影响较小,具有临床应用价值。
Objective To explore the studies on the effects of different statins on blood glucose and its mechanism. Methods A total of 120 non diabetic patients with coronary heart disease were divided into group A, group B and group C according to different treatment methods, 40 cases in each group. Group A was treated with Pitavastatin, group B was treated with Rosuvastatin, and group C was treated with Atorvastatin. After three months, the low density lipoprotein cholesterol（LDL-C）, triglyceride（TG）, total cholesterol（TC）, high density lipoprotein cholesterol（HDL-C）, fasting blood glucose, 2-hour postprandial blood glucose, glycosylatedhemoglobin and insulin value were compared among the three groups. Results Before treatment, there were no significant differences in the LDL-C, TC, HDL-C and TG among the three groups（P〉0.05）. After treatment, there were no significant differences in LDL-C, TC, HDL-C and TG between group B and group C（P〉0.05）, but the LDL-C, TC, HDL-C, TG of group A compared with group B and group C, the differences were statistically significant（P〈0.05）. Before treatment, there were no significant differences in the glycosylated hemoglobin, fasting blood glucose, insulin value and 2 h postprandial blood glucose among the three groups（P〉0.05）. After treatment, there were no significant differences in the glycosylated hemoglobin, fasting blood glucose, insulin value and 2 h postprandial blood glucose between group B and group C（P〉0.05）, but the glycosylated hemoglobin, fasting blood glucose, insulin value and 2 h postprandial blood glucose of group A were（3.89±0.70）%,（4.62±1.21） mmol/L,（27.54±24.10） m U/L and（5.98±1.23） mmol/L respectively, which were significantly lower than（4.90±0.44）%,（5.22±1.89） mmol/L,（30.90±26.60） m U/L and（6.39±1.01） mmol/L of group B,（4.32±0.51）%,（5.15±1.71） mmol/L,（30.10±25.12） m U/L and（6.22±1.22） mmol/L of group C, the differences were statistically significant（P〈0.05）
作者
刘思宁
田学峰
陈琳
徐梦
LIU Si-ning;TIAN Xue-feng;CHEN Lin(Department of Cardiovascular Medicine,Heilongjiang Provincial Hospital,Harbin 150060,China)
出处
《中国现代药物应用》
2018年第17期76-78,共3页
Chinese Journal of Modern Drug Application
基金
黑龙江省卫生计生委科研课题(项目编号:2017-468)
关键词
瑞舒伐他汀
血糖
冠心病
类异戊二烯
匹伐他汀
Rosuvastatin
Blood glucose
Coronary heart disease
Isoprenoid
Pitavastatin
